论文部分内容阅读
1征文主题厄洛替尼(Erlotinib,特罗凯)是新型、高效小分子HER1/EGFR酪氨酸激酶抑制剂,是目前在全球证实对非小细胞肺癌患者具有生存优势的EGFR-TKI靶向治疗药物,2006年在中国上市用于非小细胞肺癌患者的治疗,给广大NSCLC患者带来了生存的希望。本次征文活动旨在交流厄洛替尼的临床应用给NSCLC治疗带来的突破和临床获益,以便让更多的NSCLC患者享受特罗凯治疗的生存获益。
1 Essay Topic Erlotinib (Tarceva) is a novel and efficient small molecule HER1 / EGFR tyrosine kinase inhibitor, is currently the world’s confirmed survival of non-small cell lung cancer patients with EGFR-TKI targeted Therapeutic drugs, marketed in China in 2006 for the treatment of patients with non-small cell lung cancer, have brought hope for the survival of patients with NSCLC. The purpose of this essay is to exchange the clinical application of erlotinib for the breakthrough and clinical benefit of NSCLC in order to let more NSCLC patients enjoy the survival benefit of Tarceva treatment.